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The Plasmodium falciparum Pfs25 protein (Pfs25) is a leading malaria transmission-blocking
vaccine antigen. Pfs25 vaccination is intended to elicit antibodies that inhibit parasite
development when ingested by Anopheles mosquitoes during blood meals. The Pfs25 three-
dimensional structure has remained elusive, hampering a molecular understanding of its
function and limiting immunogen design. We report six crystal structures of Pfs25 in complex
with antibodies elicited by immunization via Pfs25 virus-like particles in human immu-
noglobulin loci transgenic mice. Our structural findings reveal the fine specificities associated
with two distinct immunogenic sites on Pfs25. Importantly, one of these sites broadly
overlaps with the epitope of the well-known 4B7 mouse antibody, which can be targeted
simultaneously by antibodies that target a non-overlapping site to additively increase parasite
inhibition. Our molecular characterization of inhibitory antibodies informs on the natural
disposition of Pfs25 on the surface of ookinetes and provides the structural blueprints to
design next-generation immunogens.
DOI: 10.1038/s41467-017-01924-3 OPEN
1 Program in Molecular Medicine, The Hospital for Sick Children Research Institute, 686 Bay St, Toronto, ON, Canada M5G 0A4. 2Department of
Biochemistry, University of Toronto, 1 King’s College Circle, Toronto, ON, Canada M5S 1A8. 3 Laboratory of Malaria and Vector Research, National Institute of
Allergy and Infectious Diseases, National Institutes of Health, 12735 Twinbrook Parkway, Rockville, MD 20852, USA. 4 Kymab Ltd., The Bennet Building
(B930) Babraham Research Campus, Cambridge, CB22 3AT, UK. 5 Atreca, 500 Saginaw Drive, Redwood City, CA 94063-4750, USA. 6 Department of
Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA. 7 Fraunhofer USA Center for Molecular Biotechnology CMB, 9
Innovation Way, Newark, DE 19711, USA. 8Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK. 9 PATH’s Malaria Vaccine Initiative, 455
Massachusetts Avenue NW Suite 1000, Washington, DC 20001, USA. 10 Department of Medicine, Division of Infectious Diseases, Imperial College London,
London SW7 2AZ, UK. 11 Department of Immunology, University of Toronto, 1 King’s College Circle, Toronto, ON, Canada M5S 1A8. Correspondence and
requests for materials should be addressed to J.-P.J. (email: jean-philippe.julien@sickkids.ca)
NATURE COMMUNICATIONS |8:  1568 |DOI: 10.1038/s41467-017-01924-3 |www.nature.com/naturecommunications 1
12
34
56
78
9
0
A major challenge for vaccine development against Plas-modium falciparum (Pf) is its complex lifecycle involvingboth an asexual stage in the human host, and a sexual
stage primarily in the Anopheles mosquito. Generally, it is
assumed that the most effective path to malaria elimination will
involve a combination of immunization strategies effective at
blocking several Pf life stages1,2. Fundamental to this idea are
transmission-blocking vaccines (TBVs), which seek to inhibit the
development of parasites in the mosquito vector to prevent its
spread back to the human population. It has been well docu-
mented that antibody interference with specific sexual stage
antigens can lead to the inhibition of Pf in Anopheles
mosquitoes3–5.
The TBV candidate antigen Pfs25, which has been tested
extensively in human trials6,7, is a glycosylphosphatidylinositol-
linked protein expressed on the surface of ookinetes8,9. Pfs25 is
important for ookinete survival in the protease-rich mosquito
midgut, assists with penetration of the mosquito epithelium, and
aids maturation of ookinetes into oocysts10,11. Pfs25 is predicted
to fold into four EGF-like domains and to contain multiple
internal disulfide bonds, but its three-dimensional structure has
not yet been solved8,12. Much of our structural understanding of
Pfs25 is based on a model derived from the homologous protein
expressed by Plasmodium vivax (Pvs25, 46% sequence identity)
for which the atomic structure is known13. Pfs25 protein is
expressed solely in the mosquito, and consequently, its low
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Fig. 1 Phylogram representation of B-cell responses to Pfs25-VLP immunization. Natively paired H- and L-chain, full-length, variable region sequences from
13 Pfs25-VLP-immunized Kymice were combined into one phylogram based on full-variable region H- and L-chain amino acid sequence similarity among
plasmablast IgG and memory B-cell IgG sequences. The 95 plasmablast-derived and 18 memory B-cell-derived sequences selected for recombinant
antibody expression are noted as green circles and blue boxes, respectively. Recombinant antibodies listed in Table 1 chosen for further analysis are
labeled. Between pairs of nodes, sum of radial distances is proportional to the Kimura distance as indicated by the scale bar. Branch color denotes the
specific animal from which the sequence was derived. Higher magnification insets show cases in which two different anti-Pfs25 antibodies of highly similar
sequence originate from different individual Kymice and, in two cases, different antibody-expressing cell types. The subset of plasmablast sequences from
Pfs25-VLP immunized Kymice that are similar to sequences from empty VLP-immunized Kymice are included as part of the 1564 plasmablast data set
shown in the tree, but were not used as sources for recombinant antibody expression
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sequence diversity between isolates is thought to be the result of
limited immune selective pressure14,15. Antibody targeting of
Pfs25 can result in a significant reduction in the number of
oocysts in in vitro membrane feeding assays16,17. The high
sequence conservation within Pf strains and the fact that anti-
bodies taken up by mosquitoes in blood meals can impede
parasite development make Pfs25 an attractive TBV target. As a
result, Pfs25 has been a leading target for vaccine design18,19.
The main challenge associated with a TBV is to elicit by human
vaccination, sufficient titers of potent antibodies to inhibit the
parasite in the mosquito gut after a blood meal20. Past attempts
using Pfs25 as an immunogen have suffered from low immuno-
genicity despite the use of various adjuvants designed to boost the
humoral antibody response6,21. A high-resolution definition of
sites of vulnerability on Pfs25 would enable the structure-guided
design of immunogens that might increase the immunogenicity of
potent epitopes.
Here we characterize monoclonal antibodies (mAbs) elicited
from the Kymouse human immunoglobulin (Ig) loci transgenic
mice, immunized with recombinant plant-produced Pfs25 virus-
like particles (VLPs)22–24. We delineate the atomic structure of
Pfs25 as recognized by six mAbs covering two distinct regions
defining functionally important epitopes. Using this information,
we identify the antibodies most effective at inhibiting oocyst
development and show that two non-overlapping epitope regions
can be targeted additively to lower individual antibody titers
required for parasite inhibition.
Results
Pfs25-specific mAbs derived from humanized mice. To develop
a molecular understanding of the antibody response to Pfs25,
Kymab mice (KymouseTM), that are transgenic for the non-
rearranged human antibody germline repertoire, were immunized
with a plant-produced Pfs25-VLP immunogen23 (Supplementary
Figs. 1 and 2). MAbs against Pfs25 were generated using direct
sequencing of expressed IgG mRNA from both Pfs25-specific
memory B cells following antigen-specific single-cell sorting and
from splenic plasmablasts without any pre-selection (Supple-
mentary Fig. 3). The anti-Pfs25 response in both cell types was
assessed to determine which compartment contains the most
functionally potent, active, or broad set of antibodies. Five hun-
dred fifty-five memory B-cell-derived mAbs were generated as
human IgG1 and screened for binding to Pfs25 by homogeneous
time-resolved fluorescence and surface plasmon resonance. Two
hundred twenty-five mAbs were confirmed by both assays to bind
Pfs25, and had affinities ranging from ~500 nM to less than 1 nM
(Supplementary Fig. 3B). In parallel, 1564 natively paired, com-
plete variable region sequences were derived from plasmablasts.
All plasmablast sequences were combined with the memory B-cell
sequences available to allow a comprehensive gene usage analysis
of both B-cell repertoires from 13 Kymice in response to
immunization with Pfs25-VLP (Fig. 1). This analysis revealed a
diverse response, spanning 784 Ig lineages across 6 VH gene
families (Fig. 1). Interestingly, anti-Pfs25 antibodies of highly
similar sequence were observed in different individual Kymice,
with 102 Ig common lineages being present in two or more
similarly immunized Kymice (Supplementary Fig. 3D). As
expected, common Ig lineages were also observed in different
antibody-expressing cell types (memory B cells and plasmablasts)
(Fig. 1 and Supplementary Fig. 3C).
Ninety-five plasmablast-derived mAbs, representing 93 unique,
putative lineages, and 18 memory B-cell-derived mAbs were
generated after downselection using sequence analyses and Ig
lineage clustering as criteria (described in “Methods” section).
Thirty-four of the 95 plasmablast-derived mAbs were confirmed
to bind to Pfs25-VLP and not empty VLP by ELISA
(Supplementary Fig. 3C). Only seven plasmablast-derived mAbs
bound to soluble Pfs25 indicating most required avidity for
binding, or Pfs25 on VLPs has epitopes not present in soluble
Pfs25 (Supplementary Fig. 3C). Based on their binding reactivity
to Pfs25-VLP and/or soluble Pfs25, 35 mAb derived from 20
plasmablast and 15 memory B cell mAbs were selected for further
functional activity in the membrane feeding assay. At a single
high concentration of 375 μg/ml (or lower, as one antibody had
limiting material), 19 showed inhibition in a single concentration
functional screen above 80% and one greater than 50%
(Supplementary Table 1). These 20 mAbs were derived from 15
independent lineages with three only found in plasmablasts, six
derived from lineages in both plasmablasts and memory B cells,
and six only from memory B cells. Ten of these antibodies were
selected for further analysis (Table 1). Based on their germline
gene usage, apparent recombination and somatic hypermutation,
the 10 antibodies bin into seven unique groups (Fig. 1 and
Table 1). Three pairs of antibodies (1190/1276, 1245/1260, and
1266/1267) constitute examples of common selection of sequence
features in the immune response of similarly immunized Kymice.
Within this subset, two mAb pairs (1190/1276 and 1245/1260)
derive from memory B cells and plasmablasts pools, providing
examples of similar B cell diversity being present in both immune
repertoires for SMFA-active mAbs (Table 1).
Binding competition reveals two antibody recognition sites. To
determine the putative-binding sites of the 10 anti-Pfs25 mAbs,
we expressed antigen-binding fragments (Fabs) of the antibodies
and performed real-time competition-binding studies by biolayer
interferometry (Fig. 2). The tested antibodies were then binned
according to their competition groups. 4B7 IgG previously had
been mapped to the B loop of the EGF-like domain 325 and was
included in the epitope-binning studies as a comparison. Epitope-
binning studies identified two distinct antibody recognition sites
Table 1 Variable gene usage of 10 SMFA-active Pfs25-specific memory B cells (MBC)-derived and splenic plasmablasts (PB)-
derived mAbs
mAb VH DH JH HCDR3 length SHM nt SMH aa VK/L JK/L LCDR3 length SHM nt SHM aa Source Mouse
1190 1–2 2–2 4 13 13 9 3–21 3 12 9 6 PB E-80-1c
1276 1–2 2–2 4 13 9 7 3–21 3 10 12 5 MBC E-80-1a
1245 1–18 4–17 6 18 14 9 2–30 4 9 5 2 PB F-87-3G
1260 1–18 n.d 6 18 17 9 2–30 4 9 2 1 MBC F-87-3b
1266 6–1 6–19 4 16 8 2 3–10 2/3 11 4 3 MBC E-80-1d
1267 6–1 6–19 4 16 7 4 3–10 3 11 6 3 MBC E-80-1a
1202 3–11 3–10 3 15 15 8 3–1 1 9 10 5 PB E-80-1c
1262 4–4 4–17 4 13 15 11 1–9 2 9 5 3 MBC F-87-3b
1268 3–21 3–10 5 17 5 4 1–9 1 9 3 3 MBC F-87-3G
1269 3–23 3–10 6 18 11 7 3–20 5 6 4 3 MBC F-87-3F
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on Pfs25, that we term sites 1 and 2. Site 1 is complex and is
recognized by eight of the 10 antibodies with four overlapping
sites, labeled a to d, highlighting a fine specificity for antigen
recognition of this immunogenic Pfs25 region. Six of the eight site
1 antibodies were in competition with 4B7 (site 1a and b anti-
bodies), likely indicating that site 1 antibodies bound to the EGF-
like domain 3 (Fig. 2). In contrast, the site 2 bin is completely
distinct from site 1; it contains two antibodies, 1245 and 1260,
and showed no interference with any of the other tested anti-
bodies. Importantly, antibodies with similar gene usage (1190/
1276, 1245/1260, and 1266/1267) segregated into the same bins,
providing further evidence of correct binning per epitope results.
Thus, SMFA-active antibodies recovered after immunizing
Kymice with Pfs25-VLP immunogens bound two distinct binding
sites, one likely centered around the EGF-like domain 3 and one
new as yet uncharacterized site.
Binding kinetics characterization of elicited antibodies. To
understand the binding characteristics of elicited anti-Pfs25
SMFA-active antibodies, we performed binding kinetics analyses
of the 10 Fabs to Pfs25 by biolayer interferometry (Supplemen-
tary Fig. 4). Fabs displayed an 18-fold difference in affinities for
Pfs25, ranging from 3.7 to 67 nM (Supplementary Fig. 4K and
Supplementary Table 2). This spread is reflected by association
rates ranging from 2.2 × 104 to 4.8 × 105 1M−1 s−1
(Supplementary Fig. 4L and Supplementary Table 2), and dis-
sociation rates ranging from 1.6 × 10−2 to 3.8 × 10−4 s−1 (Sup-
plementary Fig. 4M and Supplementary Table 2). Antibodies
1269 (KD= 3.7 nM) and 1245 (KD= 31 nM) bound site 1 and site
2, respectively, with the highest affinity within their epitope bins.
Antibody recognition of site 2 was associated with slower on-rates
and slower off-rates. The Fab affinities observed here corroborate
the binding that led to the identification of these antibodies in
initial screening (Supplementary Fig. 3B). We also note that as
IgG’s, 1269 and 1245 bind with similar avidity to Pfs25 as the 4B7
IgG (Supplementary Fig. 5). Their extremely slow off-rates pre-
vent accurate determination of their binding avidities by biolayer
interferometry, which we estimate to be <10−12 M.
Crystal structures of Pfs25 in complex with six mAbs. To
understand the fine specificity of Pfs25 antibody recognition
against sites 1 and 2, we attempted to determine co-complex
crystal structures of all antibodies tested in competition binding
studies. All antibodies recognized conformational epitopes, and
unlike mAb 4B7 did not react with linear peptides of the Pfs25
protein, or with denatured Pfs25 in western blot experiments. As
such, we focused our structural efforts on antibody–Pfs25 com-
plexes. We obtained the structures of four site 1a antibodies,
1190, 1262, 1269, and 1276, in complex with Pfs25 to 2.4, 2.7, 2.5,
and 2.2 Å resolution, respectively; and two site 2 antibodies, 1245
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Fig. 2 Epitope binning of anti-Pfs25 Kymouse-derived human antibodies. Primary antibodies tested are listed in the left column, while secondary competing
antibodies are listed at the top in rows. Data indicate the percent of competing antibody binding compared to the maximum competing antibody response
in the absence of the primary antibody. Boxes are colored according to competition status. Competing antibodies that displayed ≤ 33% maximal binding
are colored black and considered competing, between 34 and 66% binding are considered intermediate and colored gray, and those that displayed ≥ 66%
binding are colored white and considered non-competing. Epitope bins are listed above or beside the table, with site 1 competing antibodies colored in
shades of blue and site 2 competing antibodies colored green. *Primary antibodies displayed a fast off-rate, resulting in intermediate binding values for true
non-competing antibodies. ^Competing antibodies displayed a slow on-rate, leading to low values. The well-characterized mouse mAb 4B7 is highlighted in
yellow as a reference
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and 1260, in complex with Pfs25 to 1.9 and 3.3 Å resolution,
respectively (Fig. 3a–f and Supplementary Tables 3–9). These
crystal structures provide a broad molecular understanding of B
cell responses elicited by the Pfs25-VLP immunogen in Kymice.
As indicated in the competition-binding data, site 1a antibodies
bound to the EGF-like domain 3 (Fig. 3g, green domain), while
site 2 antibodies bound to the triangular face of Pfs25—a pre-
viously uncharacterized antigenic site of Pfs25—contacting all
four EGF-like domains (Fig. 3h).
These crystal structures represent the first three-dimensional
structural delineation of the TBV Pfs25 antigen. Comparison of
the structures of Pfs25 in each complex to the previously
determined Pvs25 structure (Supplementary Fig. 6A)13 showed
that Pfs25 adopts a similar overall structure as Pvs25, in which
four distinct EGF-like domains assume a triangular arrangement
and disulfide-bonding patterns are conserved (Supplementary
Fig. 6B). The six Pfs25 structures superposed well, displaying a
low average root mean square deviation (RMSD) of 0.8 Å. The
RMSD was highest in the loop regions of the EGF-like domains
(Supplementary Figs. 6C and 7). Differences between the six
Pfs25 structures and Pvs25 (Supplementary Fig. 6D) were
considerably greater (overall RMSD= 2.1 Å), particularly in the
EGF-like domain 4 (RMSD= 4.0 Å, Supplementary Fig. 6C). Of
note, residues that promote the characteristic triangular archi-
tecture are either conserved between Pfs25 and Pvs25, or in the
case of residues Glu/Lys22 and Lys/Glu98, are swapped between
homologs therefore adopting similar conformations (Supplemen-
tary Fig. 6E).
Specificities of site 1-directed mAbs. Site 1a mAbs 1190, 1262,
1269, and 1276 recognize the EGF-like domain 3 of Pfs25 and
compete for largely overlapping recognition sites (Fig. 4a). We
compared the angle of approach of site 1a mAbs by calculating
and comparing the center of mass of the variable domains of the
antibodies with their respective Pfs25-interacting residues
(Fig. 4b), and noted varied binding modes for recognition of the
EGF-like domain 3. MAbs 1190 (plasmablast-derived from
Pfs25 Pfs25
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Fig. 3 Crystal structures of six mAbs in complex with Pfs25. Crystal structures of a 1190, b 1276, c 1262, d 1269, e 1245, and f 1260 in complex with Pfs25.
All crystal structures are shown according to the same Pfs25 orientation. Pfs25 is represented as surface and EGF-like domains 1–4 are colored in wheat,
pink, green, and blue, respectively. g Site 1a epitopes for 1190, 1262, 1269, and 1276 antibodies traced onto the surface of Pfs25. h Site 2 epitopes for 1245
and 1260 antibodies traced onto the surface of Pfs25
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Kymouse E-80-1c) and 1276 (memory B cell-derived from
Kymouse E-80-1a) are part of a mAb pair, and differ by eight H-
chain and 14 L-chain residues. Of these residues, two in the
HCDR2 (Thr/Asn53 and Asp/Ser54) and one each in the LCDR2
(Tyr/Phe52) and LCDR3 (His95B/Arg95) contact Pfs25.
Accordingly, 1190 and 1276 demonstrated similar interacting
buried surface areas (BSA, 1136.8 and 1104.0 Å2) and hydrogen
(H)-bonding networks (17 and 14 H-bonds, respectively) (Fig. 4c,
d and Supplementary Tables 4 and 5). In addition, their H- and
L-chains contributed almost equally to Pfs25 contacts and BSA
(Supplementary Table 10). The slightly greater BSA and H-bonds
of 1190 compared to 1276, likely explain the higher affinity 1190
exhibits compared to 1276 (6.7 nM vs. 16 nM, Supplementary
Table 2). Thus, 1190 and 1276 bind to Pfs25 similarly, and
approach Pfs25 from the same direction, contacting pre-
dominantly EGF-like domain 3 residues, but also residues 75, 76,
77, and 78 from the EGF-like domain 2 (Supplementary Tables 4
and 5). 1190 and 1276 are examples of paratope fit driving
convergent selection in the germinal centers of two different
Kymice (Table 1).
Despite a rotation of ~173° compared to 1190/1276, mAb 1262
only shifts its center of mass by 3.5° effectively swapping its
variable L- and H-chain domains with the H- and L-chains of
1190/1276 (Fig. 4b). 1262 contacts EGF-like domain 3 residues
exclusively (Fig. 4e, Supplementary Table 6). 1262 exhibited the
lowest BSA of the site 1a mAbs (929.6 Å2), with the H-chain
contributing slightly more BSA (534.8 Å2 vs. 394.8 Å2) and H-
bonds (9 vs. 6) compared with its L-chain (Supplementary
Table 10). In contrast, mAb 1269 demonstrates an angular
difference of 31° and 35° in its angle of approach compared to
1190/1276 and 1262, respectively, resulting in 1269 contacting
EGF-like domain 1 residues 18 and 19 (Fig. 4b, f and
Supplementary Table 7). In addition, contacts between antibody
1269 and Pfs25 are dominated by its H-chain, which contributes
889.5 Å2 of BSA and 17 H-bonds compared to its L-chain (239.5
Å2 and two H-bonds). As 1269 is the only site 1a mAb that co-
resides in the site 1b and 1c bins, it is likely that site 1b and 1c
mAbs also recognize these unique EGF-like domain 1 residues of
Pfs25. MAb 1269 exhibited the greatest number of H-bonds of
the site 1a mAbs, which together with its high BSA, helps explain
its highest-binding affinity for Pfs25 compared to the other site 1a
mAbs (Supplementary Fig. 4 and Supplementary Tables 2 and
10). Interestingly, an intricate H-bonding network between the
HCDR2 of 1269 and Pfs25 residue Glu88 led to a unique
rotameric state for this antigen residue compared to recognition
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Fig. 4 Molecular details of site 1a antibody recognition. a Superposition of site 1a antibody–Pfs25 co-complex crystal structures. Pfs25’s are shown as
cartoon and colored according to EGF-like domain as in Fig. 3. 1190, 1262, 1269, and 1276 Fabs are shown as surface representation and colored in yellow,
blue, orange, and teal, respectively. b Comparison of the angle of approach. The center of mass for both the Fab variable domains and interacting Pfs25
residues are shown as spheres and colored as in a. CDR loops that interact with Pfs25 for c 1190, d 1276, e 1262, and f 1269. Non-interacting Pfs25 residues
are colored gray, while interacting residues are colored according to their EGF-like domain as in a
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Fig. 5 Molecular details of site 2 antibody recognition. a Superposition of
site 2 antibody–Pfs25 co-complex crystal structures. Pfs25s are shown as
cartoon and colored according to EGF-like domain as in Fig. 3. 1245 and
1260 Fabs are shown as surface representation and colored in salmon and
brown, respectively. b Comparison of the angle of approach. The center of
mass for both the Fab variable domains and interacting Pfs25 residues are
shown as spheres and colored as in a. CDR loops that interact with Pfs25
for c 1245 and d 1260. Non-interacting Pfs25 residues are colored gray,
while interacting residues are colored according to their EGF-like domain
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by the other three antibodies against the same sub-site, resulting
in a more electronegative surface targeted by 1269 (Supplemen-
tary Fig. 8). Crystals for Pfs25 in complex with site 1b, 1c, and 1d
mAbs 1202, 1266, 1267, and 1268 remain elusive, and therefore
the exact composition of their epitopes is still to be uncovered. In
summary, the site 1a antibodies described here contact 17
common residues, which represent a critical immunogenic site on
Pfs25 (Supplementary Fig. 9).
Specificities of site 2-directed mAbs. Site 2 mAbs 1245 (plas-
mablast-derived from Kymouse F-87-3G) and 1260 (memory B
cell-derived from Kymouse F-87-3b) are examples of convergent
selection in two different Kymice (Table 1), and share 84 and 96%
sequence identity in the variable regions of their H- and L-chains,
respectively. Interestingly, our crystal structures reveal that none
of the differing amino acids contact Pfs25 with their sidechains.
Therefore, 1245 and 1260 bind to Pfs25 very similarly, adopt a
similar angle of approach to one another, and importantly,
contact all four EGF-like domains (Fig. 5a, b). 1245 and 1260
demonstrated a smaller interaction site compared to site 1a
mAbs, with BSAs of 803.1 Å2 and 847.6 Å2, respectively (Sup-
plementary Table 10). The smaller interface likely contributed to
their lower binding affinities (Supplementary Fig. 4 and Supple-
mentary Table 2). Their interactions with Pfs25 were pre-
dominantly mediated by their HCDR3 (Fig. 5c, d and
Supplementary Tables 8 and 9), which contributed eight out of
the total 14 H-bond partners for 1245, and seven out of the total
12 H-bond partners for 1260 (Supplementary Table 10). Notably,
the LCDR3 of these antibodies did not contact Pfs25 (Fig. 5c, d).
We also note that none of the site 1a and site 2 mAbs described
here bind to the antigenic site recognized by the Pvs25-reactive
2A8 mAb (Supplementary Fig. 10).
Role of somatic hypermutations in anti-Pfs25 mAbs. To
determine the role of affinity maturation in Pfs25 recognition, we
analyzed the sequence differences between the mature antibodies
and their germline precursors, which is known for the Kymouse.
Our analysis reveals that mAbs underwent between 2 and
11 somatic hypermutations (SHM) in their H-chains and between
one and six SHMs in their L-chains compared to germline
(Table 1). Analysis of the site 1a and site 2 mAb crystal structures
demonstrates the effect these mutations have on Pfs25 recogni-
tion. Site 1a mAbs typically acquired 1–2 mutations that led to
additional H-bonds or van der Waals interactions (Fig. 6). In
mAb 1269, this includes a S31R mutation in the HCDR1 and a
G55D mutation in the HCDR2 that introduce three and one H-
bonds, respectively (Fig. 6a, b). In mAb 1262, a S30N mutation in
the LCDR1 leads to an additional H-bond with Pfs25 residue
Asn105 (Fig. 6c). In mAb 1190, a S54D mutation in the HCDR2
leads to an additional H-bond (Fig. 6d), while both 1190 and 1276
each have an S52F/Y mutation that introduces van der Waals
contacts with multiple EGF-like domain 2 residues, and ensures
that Asn87 adopts a favorable conformation to H-bond with
other LCDR2 residues (Fig. 6e, f). In contrast and somewhat
surprisingly, site 2 mAbs 1245 and 1260 apparently displayed no
SHM that led to additional contacts with Pfs25. However,
changes in framework regions may have contributed to re-
shaping the antibody paratopes leading to increased affinity.
Additionally, both 1245 and 1260 interact with Pfs25 pre-
dominantly through their HCDR3; therefore, our inferred ana-
lysis of SHM may have missed important B cell ontogeny
mutations in the 5–6 residues encoded in the non-templated VD
and DJ junctions within the HCDR3.
mAbs against the two sub-sites are additive in SMFA. We next
quantified the inhibition potency of the mAbs, and evaluated
whether combinations of the mAbs that target sites 1 and 2 would
exhibit additive or synergistic inhibition activity in SMFA. We
determined the specific potency of the two mAbs with the highest
binding affinity against sites 1 and 2, 1269 and 1245, respectively
(Feed #1 and #2; Fig. 7a and Supplementary Table 11). In
agreement with previous studies with monoclonal and polyclonal
antibodies26–28, there was a linear dose response for each mAb
when the ratio of mean oocyst count (right y-axis, on a log-scale)
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Fig. 6 Affinity maturation of mAbs at the binding interface. Somatic hypermutations (SHMs) that introduce new contacts with Pfs25 are colored dark gray.
a A S31R mutation in the HCDR1 of 1269 introduces two H-bonds with Pfs25 residues T93 and Q125. b A G55D mutation in the HCDR2 of 1269 introduces
an additional H-bond with Pfs25 residue N87. c A S30N mutation in the LCDR1 of 1262 leads to an additional H-bond with Pfs25 residue N105. d A S54D
mutation in the HCDR2 of 1190 leads to an additional H-bond contact with Pfs25 residue Q123. e A S52Y mutation in the LCDR2 of 1190 leads to additional
van der Waals interactions with Pfs25 residues, and ensures that N87 hydrogen bonds with adjacent LCDR2 residues. f Similar to 1190, 1276 has a S52F
mutation in the LCDR2 that leads to additional van der Waals contacts with Pfs25 residues, and ensures that N87 hydrogen bonds with adjacent LCDR2
residues
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was plotted against the square root of antibody concentration (x-
axis). MAb 1269, with an IC80 of 63 μg/ml (95% CI, 53–75), was
significantly more potent than 1245, with an IC80 of 263 μg/ml
(95%CI, 211–348), in accord with the higher binding affinity of
1269 (Supplementary Table 2). IC80 was used as an adequate
measure because the SMFA assay becomes highly variable below
the 80% inhibition level. In comparison, the IC80 of 4B7 was 29
μg/ml (95% CI, 24–34).
To design combination experiments for mAbs against sites 1
and 2, we determined concentrations at which both mAbs show
similar levels of transmission-reducing activity (%TRA). Since
1269 was more potent than 1245 (Fig. 7a), higher concentrations
of 1245 than 1269 were used in subsequent co-administration
feeds. At the lowest concentration, a mixture of 31 μg/ml of 1245
and 4 μg/ml of 1269 were fed to mosquitoes (31-4 mixture
group). These individual antibody concentrations correspond to
37% TRA when tested alone. Following the same scheme, three
more mixture groups were tested: 45-7 (45% TRA by either single
antibody), 73-13 (56% TRA), and 132-27 (69% TRA) mixture
groups. In the next feeding assays, the antibodies were fed either
alone or as mixtures (Feed #3 and #4; Fig. 7b, c and
Supplementary Table 12). At the higher doses (73-13 and 132-
27 combinations), the two mAbs showed significantly higher %
TRA than the corresponding single antibody groups (up
~20–30%, Fig. 7b, c). Since the SMFA has lower precision for
weaker activity samples26,28, the results of co-administration at
the lower doses (31-4 and 45-7 combinations) are less certain, but
still trend toward higher %TRA when the two mAbs are co-
administered. In summary, we interpret our results to indicate
that the two mAbs worked additively, as the observed %TRAs in
the mixture groups were clearly similar to the levels expected for a
theoretical additive effect (Fig. 7b, c).
Discussion
An effective TBV for malaria will need to elicit high titers of
potent antibodies in humans to effectively inhibit parasite
development in mosquitoes6. Our molecular and functional
analyses of the antibody response from Kymice Ig-humanized
mice after immunization with plant-expressed Pfs25-VLP reveal
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two distinct immunogenic sites on Pfs25. Site 1 broadly overlaps
the well-characterized 4B7 epitope in the EGF-like domain 3,
while site 2 is a newly identified immunogenic site that spans the
four EGF-like domains of Pfs25. Our highest-affinity SMFA-
active mAb against site 1, 1269 (3.7 nM affinity as Fab, <10−12 M
avidity as IgG), is more potent in TRA than the highest-affinity
SMFA-active mAb isolated against site 2, 1245 (31.0 nM affinity
as Fab, <10−12 M avidity as IgG).
Our molecular characterization of functional mAbs against
Pfs25 informs on the arrangement of the antigen on the surface of
ookinetes. It is reasonable to assume that antibody inhibition of
the development of ookinetes can only occur if their epitopes on
Pfs25 are exposed and accessible on the cell surface. Saxena
et al.13 had previously suggested a model that featured Pvs25
coating the cell surface of ookinetes in a tile-like fashion inferred
from crystal packing interactions combined with residue con-
servation analyses. Our structural data shows that site 1-directed
mAbs (e.g., 1269), which are active in SMFA, recognize a face of
Ps25 that is buried and inaccessible at the interface of the Pvs25
tile-like model (Supplementary Fig. 11), arguing against the tile-
like model for Pfs25. The epitopes of site 2-directed mAbs (e.g.,
1245) are somewhat accessible in the tile-like model (Supple-
mentary Fig. 11), but the fact that site 2 mAbs are less potent
inhibitors than site 1 mAbs further argues against this arrange-
ment of Pfs25 on the ookinetes surface.
The Kymouse provides a model system for the characterization
of B cell responses in a humanized immune setting and have been
successful in this regard in diseases such as HIV24. Here we report
to our knowledge the first crystal structures of Kymouse-derived
antibodies to their cognate antigen. Our results support the wide
diversity of the B cell repertoire reported for the Kymouse22.
Memory B cell- and plasmablast-derived mAbs displayed a varied
gene usage, bound to at least two distinct immunogenic sites,
displayed binding affinities spanning the nanomolar range, and
underwent affinity maturation, indicating TFH cell help in
germinal centers29. The mAbs also showed a range of BSAs to
both predominantly single-domain (antigenic site 1a) and more
elaborate multi-domain (antigenic site 2) epitopes, as well as
recognition modes that employ equal H- and L-chain contribu-
tions (1190 and 1276), or H-chain-dominated interactions (1245,
1260, and 1269). Our data show that both memory B cell- and
plasmablast-derived mAbs contain functional antibodies. It is
therefore likely they both contribute to the serum polyclonal
response (from short- and long-term plasma cells) and therefore
may also be part of a long-lived response, which is an important
goal in the development of a durable TBV. Characterization of
the antibody response to the same Pfs25 immunogen in humans
will be an important next step to compare and further validate the
Kymouse as a predictive model system to evaluate immuno-
genicity of TBV candidates.
Our six crystal structures revealed that the loop regions of the
EGF-like domains, including the 4B7 loop, are not rigid; instead,
they are capable of adopting multiple conformations, providing
important knowledge for immunogen design seeking to elicit B
cell responses against the most potent Pfs25 conformation.
Importantly, both Pfs25 immunogenic sites uncovered in our
studies can be targeted simultaneously and when 1269 and 1245
are co-administered in SMFA, they act additively to reduce the
concentration of individual antibody required to achieve the same
transmission-reducing activity. We note, however, that 1269 is
considerably more potent than 1245, therefore the required
concentration for TBV activity for 1269 alone is much lower than
for a 1245/1269 mixture. It is possible that site 2 mAbs of equal
potency to site 1 mAbs exist but were not identified in our studies
and such antibodies might be revealed by additional data mining.
Additionally, it is possible that other sites exist that also elicit
potent mAbs. Indeed, it has been shown that EGF-like domain 2
is sensitive to the transmission-blocking activity of antibodies,
even at low titers compared to other antigenic sites on Pfs258.
Nevertheless, our data currently support immunogen design
approaches that focus the immune response on antigenic site 1
(e.g., ref. 30) to preferentially elicit 4B7- and 1269-like mAbs,
while also highlighting the benefits of polyclonal responses that
can act additively. An understanding of the Pfs25 three-
dimensional structure and the location of protective epitopes
will also enable the optimal display and density of Pfs25 on
nanoparticles, which is known to significantly boost B cell
responses31–34.
Analogous to other disease models, such as respiratory syn-
cytial virus (RSV)35,36 and HIV31,37,38, the crystal structures
presented here can serve as blueprints for epitope-focusing efforts
and provides critical insights to guide the design of malaria
transmission-blocking therapeutic or prophylactic antibodies.
Methods
Antigens and immunizations. Antigen was provided as a VLP with surface-
displayed Pfs25 (Fraunhofer CMB, Newark, DE). An “empty” VLP preparation was
also supplied to act as a control for any non-Pfs25 antigens present on the VLP
vehicle. Monomeric Pfs25 was generated in Nicotiana benthamiana as previously
described39. Fourteen HK (five females and nine males) and fourteen HL (five
females and nine males) 9-week-old mice were immunized22. All mice were
maintained, and all procedures carried out under United Kingdom Home Office
License 70/8718 and with the approval of the Sanger Institute Animal Welfare and
Ethical Review Body. The immunization regimen consisted of three IP immuni-
zations performed on days 0, 21, and 42 using 1 µg of Pfs25-VLP formulated in
Montanide ISA720 (70% v/v, Seppic Inc), and a final boost at day 72 with 1 µg of
unadjuvanted Pfs25-VLP, also administered IP. Terminal peripheral blood and
splenocytes were collected on day 79. Polyclonal antibody responses directed to
Pfs25-VLP, empty VLP, and soluble Pfs25 were determined throughout the
immunization phase by ELISA. Upon completion of the immunization regimen, all
mice had developed detectable anti-Pfs25 antibody titers. Transmission-reducing
activity (TRA) was determined by SMFA using polyclonal mouse sera and
monoclonal antibodies that bound Pfs25.
Identification and selection of Pfs25-specific mAb sequences. Single-cell sus-
pensions were prepared from spleens of Pfs25-VLP-immunized mice and were
sorted to identify antigen-specific memory B cells (using the sorting markers CD19
+; IgM−; IgD−; CD38+; CD95+, APC-labeled soluble Pfs25) or plasmablasts/plasma
single cells (using the sorting markers CD138high; IgM−; IgD−; IgA−; CD3−). For
each mouse spleen, the following fluorophore-conjugated antibodies were used: 4
μL CD19 (6D5, Pacific Blue, Biolegend, Cat. No. 115523), 3 μL IgM (RMM-1,
APC-Cy7, Biolegend, Cat. No. 406516), 3 μL IgD (11-26c.2a, APC-Cy7, Biolegend,
Cat. No. 405716), 3 μL CD38 (90, FITC, eBioscience, Cat. No. 11-0381-81), 4 μL
CD95 (Jo2, PE, BD Bioscience, Cat. No. 554258). Eighty 96-well plates were sorted
from 11 immunized Kymice and antigen-specific B cells were processed by PCR to
amplify Ig H- and L-chain sequences for sequencing. Ig sequences were transfected
into HEK293 cells (Expi293F™ Cells, Gibco, Cat. No. A14635) for antibody
expression as described below.
Atreca’s Immune Repertoire Capture® (IRC™) was used to obtain full-length,
natively paired, H- and L-chain variable region sequences from single plasmablasts
[CD138high (BV420, Biolegend, 142508, 1.3 μg/ml); IgM− (APC, Biolegend, 406509,
1.3 μg/ml); IgD− (APC-Cy7, Biolegend, 405716, 1.3 μg/ml); IgA (PE, eBioscience,
12-4204-82, 1.3 μg/ml); CD3− (FITC, Biolegend, 100204, 3.3 μg/ml)] of 13 Pfs25-
VLP immunized (1564 paired H- and L-chain antibody sequences) and 14 empty-
VLP immunized (1437 pairs) Kymice. Cell lysis, reverse transcription, PCR,
barcode assignment, sequence assembly, V(D)J assignment, and identification of
mutations were performed as described previously40,41 with the following
modifications: biotinylated Oligo(dT) was used for reverse transcription, cDNA
was extracted using Streptavidin C1 beads (Life Technologies), PCR primers
against mouse gamma, kappa, and lambda constant region sequences replaced
human constant region primers, DNA concentrations were determined using
qPCR (KAPA SYBR® FAST qPCR Kit for Titanium, Kapabiosystems), and a
minimum coverage of 10 reads was required from each chain assembly to be
included in the sequence repertoires. V(D)J assignment and mutation identification
was performed using an implementation of SoDA42.
Paired H- and L-chain sequences within each Pfs25-VLP-immunized mouse
plasmablast repertoire were assigned to the same cluster if the H-chain V-gene,
HCDR3 length, L-chain V-gene, and LCDR3 length were identical. H- and L-chain
CDRs, as defined43, were identified by aligning protein sequences to a hidden
Markov model44. Sequences were further separated into putative lineages based on
the degree of identity of the HCDR3 and LCDR3 sequences. Lineages that were also
observed as expanded in the plasmablast repertoires of Kymice immunized with
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empty VLP preparation were excluded from further consideration. The remaining
lineages were scored based on plasmablast cell clone frequency in the origin
repertoire (score proportional to abundance), the degree of SHM in the complete
H- and L-chain variable regions (score proportional to degree of SHM), and
apparent convergent selection across animals. One or two paired H- and L-chain
sequences were selected for expression from each of the 93 lineages that received
the highest scores. Selected sequences were either from the plasmablast clone in the
lineage with the highest identity to the consensus sequence of the lineage or from
the clone expressed by the greatest number of plasmablasts in the lineage.
Expression and purification of Kymouse-derived IgGs. Memory B cell-derived
antibodies were expressed without purification and cloning, with antibody super-
natant collected on day 8 after transfection and screened for binding to Pfs25 by
homogeneous time-resolved fluorescence (HTRF) and surface plasmon resonance
(SPR). 225 of 555 expressed and screened antibodies showed binding by homo-
geneous time-resolved fluorescence and surface plasmon resonance and Ig H- and
L-chain sequences were obtained for 110 Pfs25-binding antibodies.
In addition, plasmablast and memory B cell-derived antibodies were
synthesized by LakePharma, Inc. (Belmont, CA). Each gene sequence was cloned
into LakePharma’s proprietary high-expression mammalian vector. Briefly, variable
regions were synthesized and subcloned into expression vectors containing the
appropriate IgG1 H- and L-chain constant region sequences. Each construct was
transiently transfected into HEK293 cells. The conditioned media from the
transient production run was harvested and clarified by centrifugation and
filtration. The supernatant was loaded over a Protein A column. The antibody was
eluted with a low pH buffer. Purified antibodies were dialyzed against PBS and
analyzed using LabChip GXII. Antibodies were screened for binding against Pfs25-
VLP, empty VLP, and soluble Pfs25 using an ELISA format assay. Positives for
further analysis were identified by binding to Pfs25 or Pfs25-VLP, but not to the
empty VLP with a signal of greater than tenfold the background level.
Expression and purification of Kymouse-derived Fabs. VL and VH regions
(sequences available in Supplementary Data 1) were cloned into pFUSE expression
vectors (Invivogen) upstream of human Igκ, Igλ, or Igγ1 CH1 constant regions, as
appropriate. Fabs were transiently expressed in HEK293F cells (Thermo Fisher
Scientific, Cat. No. R79007) and purified via KappaSelect or LambdaSelect affinity
chromatography (GE Healthcare), followed by cation exchange chromatography
(MonoS, GE Healthcare) and size exclusion chromatography (Superdex 200
Increase 10/300 GL, GE Healthcare).
BLI-binding studies. Biolayer interferometry (Octet RED96, FortéBio) experi-
ments at 25 °C were conducted to determine the epitope bins and binding kinetics
of selected Fabs for Pfs25. For competition studies, Nicotiana benthamiana-pro-
duced Pfs25 was diluted into kinetics buffer (PBS, pH 7.4, 0.01% (w/v) BSA, 0.002%
(v/v) Tween-20) at 10 μg/mL and immobilized onto Ni-NTA (NTA) biosensors
(FortéBio). Following a 30 s baseline step, biosensors were dipped into wells con-
taining the primary antibody (10 μg/mL) for 10 min, followed by another 30 s
baseline, and then dipped into wells containing the secondary antibody (10 μg/mL)
for 5 min. Similarly, for binding kinetic studies, Nicotiana benthamiana-produced
Pfs25 was diluted into kinetics buffer and immobilized onto Ni-NTA (NTA)
biosensors (FortéBio). Following a 60 s baseline step, biosensors were dipped into
wells containing twofold dilution series of Fab or IgG. Sensors were then dipped
back into kinetics buffer to monitor the dissociation rate. Competition and kinetics
data were analyzed using FortéBio’s Data Analysis software 9.0, and kinetic curves
were fitted to a 1:1 binding model. Mean kinetic constants reported are the result of
three independent experiments.
Co-crystallization and structure determination. For crystallization studies, a
Pfs25 construct with potential N-linked glycosylation sites at residue positions 91,
144, and 166 mutated to Gln was cloned into the pHLsec vector via AgeI and KpnI
sites. Pfs25 was transiently expressed in HEK293F cells and purified via a 5 mL
HisTrap FF column (GE Healthcare), followed by size exclusion chromatography
(Superdex 200 Increase 10/300 GL, GE Healthcare). Purified Fabs and Pfs25 were
mixed in a 1:2 molar ratio and excess Pfs25 was purified away via size exclusion
chromatography (Superdex 200 Increase 10/300 GL, GE Healthcare). Fab-Pfs25
complexes were then concentrated to 10 mg/mL and mixed 1:1 with mother liquor
and setup in hanging or sitting drop crystallization experiments. 1190-Pfs25
crystals grew in 0.085M Tris pH 8.5, 0.17M sodium acetate, 25.5% (w/v) PEG
4000, and were cryoprotected in 15% (v/v) glycerol. 1245-Pfs25 crystals grew in
0.1 M citric acid pH 5.0, 1 M lithium chloride, 20% (w/v) PEG 6000 and were
cryoprotected in 20% (v/v) glycerol. 1260-Pfs25 crystals were grown in 2.0 M
ammonium sulfate, 0.1 M Tris pH 8.5 and were cryoprotected in 15% (v/v)
ethylene glycol. 1262-Pfs25 crystals grew in 0.2 M magnesium acetate and 20% (w/
v) PEG 3350 and were cryo-protected with 20% (v/v) glycerol. 1269-Pfs25 crystals
grew in 0.2 M di-ammonium hydrogen citrate and 20% (w/v) PEG 3350 after
microseeding from thin needle-like crystals that grew in 0.1 M Tris pH 7.0, 0.2 M
sodium chloride, 30% (w/v) PEG 3000. 1276-Pfs25 crystals grew in 0.2 M di-
ammonium hydrogen phosphate and 18% (w/v) PEG 3350 and were cryoprotected
in 10% (v/v) glycerol. Data were collected at the 08ID-1 beamline at the Canadian
Light Source (CLS), processed, and scaled using XDS45. The structures were
determined by molecular replacement using Phaser and using Pvs25 as a search
model46. Refinement of the structures was carried out using phenix.refine47 and
iterations of refinement using Coot48. All software were accessed through
SBGrid49. No crystals that led to high-resolution structures were obtained for 1202-
Pfs25, 1266-Pfs25, 1267-Pfs25, and 1268-Pfs25 complexes.
SMFA. Antibodies were buffer exchanged in phosphate-buffered saline (PBS) and
tested at multiple concentrations in SMFA (Anopheles stephensi (Nijmegen strain))
as previously described26. Four independent feeding experiments were conducted.
In the first two feeds (Feed #1 and #2), 1245 and 1269 mAbs were tested alone (n =
20 mosquitoes per condition). In Feed #3 and #4, the two mAbs were examined
either alone (n= 20) or as mixtures. A mixture condition of 1245 (31 μg/ml) and
1269 (4 μg/ml) was tested once in Feed #3 (n = 20), and the other three conditions
(45-7, 73-13, and 132-27 μg/ml for 1245–1269, respectively) were tested in two
feeding experiments (n= 20 in Feed #3, and n= 40 in Feed #4).
Statistical analysis. The best estimate and 95% confidence intervals (95% CIs) of
%TRA in mean oocyst density, and the p value (whether the observed %TRA was
significantly different from no inhibition) for each feed or combination of two
(Feed #3 and #4) were calculated using a zero-inflated negative binomial model50.
Using the same model, we evaluated whether a mixture of two antibodies showed
higher %TRA (fewer oocysts) than a single antibody, for each mixture condition.
For each antibody, the best-fit line (shown in Fig. 7b, c) and IC80 values were
calculated using all four feeding data shown in Fig. 7a. The theoretical additive
effect (Bliss independence model; i.e., assuming the two mAbs act independently)
was also determined by the line fits.
Data availability. The crystal structures reported in this manuscript have been
deposited in the Protein Data Bank, www.rcsb.org (PDB ID codes 6AZZ, 6B08,
6B0A, 6B0E, 6B0G, and 6B0H). The authors declare that all other data supporting
the findings of this study are available within the article and its Supplementary
Information files, or are available from the authors on request.
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